Literature DB >> 4027167

The effects of pretreatment of human tumour cells with MNNG on the DNA crosslinking and cytotoxicity of mitozolomide.

N W Gibson, L C Erickson.   

Abstract

Mitozolomide and its decomposition product MCTIC were found to be more cytotoxic to BE colon carcinoma cells in vitro than to HT-29 cells, another colon carcinoma cell line. In addition mitozolomide and MCTIC induced DNA interstrand crosslinks in the BE but not the HT-29 cell line. BE cells are deficient in the repair of O6-methylguanine lesions and are designated Mer-, whereas, HT-29 cells are proficient in this repair process and are designated Mer+. Thus DNA interstrand crosslinking produced by mitozolomide and MCTIC appears to correlate with the Mer phenotype. Pretreatment of HT-29 cells (Mer+) with the DNA methylating agent MNNG allows mitozolomide or MCTIC to produce DNA interstrand crosslinks. HT-29 cells also become more sensitive to the cell killing of mitozolomide and MCTIC with MNNG pretreatment. Pretreatment of Mer- cells (BE) had little effect on either cell killing or DNA crosslinking levels induced by mitozolomide or MCTIC. DNA interstrand crosslinking induced by mitozolomide and MCTIC is probably a consequence of an initial alkylation at the O6-position of guanine followed by a delayed reaction with the opposite DNA strand.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027167      PMCID: PMC1977104          DOI: 10.1038/bjc.1985.185

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  5-[3-(2-Chloroethyl)-1-triazenyl] imidazole-4-carboxamide and a possible mechanism of action of 5-[3, 3-bis(2-chloroethyl)-1-triazenyl] imidazole-4-carboxamide.

Authors:  Y F Shealy; C A O'Dell; C A Krauth
Journal:  J Pharm Sci       Date:  1975-01       Impact factor: 3.534

2.  Cross-linking of DNA induced by chloroethylnitrosourea is presented by O6-methylguanine-DNA methyltransferase.

Authors:  P Robins; A L Harris; I Goldsmith; T Lindahl
Journal:  Nucleic Acids Res       Date:  1983-11-25       Impact factor: 16.971

3.  DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells.

Authors:  L C Erickson; G Laurent; N A Sharkey; K W Kohn
Journal:  Nature       Date:  1980-12-25       Impact factor: 49.962

4.  Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.

Authors:  M F Stevens; J A Hickman; R Stone; N W Gibson; G U Baig; E Lunt; C G Newton
Journal:  J Med Chem       Date:  1984-02       Impact factor: 7.446

5.  Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts.

Authors:  C Zlotogorski; L C Erickson
Journal:  Carcinogenesis       Date:  1984-01       Impact factor: 4.944

6.  Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Authors:  R S Day; C H Ziolkowski; D A Scudiero; S A Meyer; A S Lubiniecki; A J Girardi; S M Galloway; G D Bynum
Journal:  Nature       Date:  1980-12-25       Impact factor: 49.962

7.  Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one on the DNA of mouse L1210 cells.

Authors:  N W Gibson; L C Erickson; J A Hickman
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

8.  Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts.

Authors:  T P Brent
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

9.  Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas.

Authors:  K W Kohn
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

10.  Reactions of 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in aqueous solution.

Authors:  R J Weinkam; H S Lin
Journal:  J Med Chem       Date:  1979-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.